Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
about
Human polyomavirus reactivation: disease pathogenesis and treatment approachesDefects in mucosal immunity leading to Crohn's diseaseCrohn's disease: an immune deficiency stateInterventions for induction of mucosal healing in ulcerative colitisInterventions for maintenance of mucosal healing in ulcerative colitisMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainAutoantibody profile in rheumatoid arthritis during long-term infliximab treatmentOn the genetic involvement of apoptosis-related genes in Crohn's disease as revealed by an extended association screen using 245 markers: no evidence for new predisposing factorsOral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel diseaseNew insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathyGranuloma formation in pulmonary sarcoidosisClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateMolecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseasesPharmacogenetics in inflammatory bowel diseaseSmoking and tuberculosis: the epidemiological association and immunopathogenesisReview article: Infliximab therapy for inflammatory bowel disease--seven years onTranslational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory DiseasesBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Medical management of Crohn's disease: current therapy and recent advances.Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitisRefractory lymphocytic enterocolitis and tumor necrosis factor antagonist therapy.Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinaseTumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel diseaseRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.Infliximab for autoimmune inner ear disease: case report and literature review.Infliximab: the evidence for its place in therapy in ulcerative colitis.IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.New players in the cytokine orchestra of inflammatory bowel disease.Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation.New biologics in the management of Crohn's disease: focus on certolizumab pegol.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.[Etiopathogenesis of chronic inflammatory bowel diseases. Role of the immune system].Monomeric IgA can be produced in planta as efficient as IgG, yet receives different N-glycans.Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma.
P2860
Q21285083-6372CED5-CBE3-4751-8469-BC548DCDA728Q22242645-CBAB5C85-53D3-42C6-872A-FE37F0C7E580Q22252579-2986C3A1-95DD-4ECF-B1D7-64B4E662B12CQ24200747-36F8BAA7-49E3-47AF-9D6A-A6A7168C0368Q24200760-75813309-C8FD-4FE3-94A0-E0BFEC500A2BQ24619923-431CF5E1-86FC-4FA9-8C27-0D718614AF11Q24800888-C280ECCA-518F-44CA-BB71-C3AD3B3D9107Q24812542-C1598DA4-827A-4F62-88E7-5AFF39C6C953Q26768500-B46E605D-4E4B-4834-9360-2F14F142ECB3Q26822247-8A25B73C-32E8-4DB2-BA9B-DF8D56FD4FD3Q26863703-8728CBBF-816F-4FF2-B863-47D77859AE98Q26994776-CFF77897-2344-4012-A885-E7FA3B69EF81Q28067245-DA9BC358-66F6-4429-AD0E-F82D8B53289EQ28246002-3F5AFDB1-9C35-478C-807C-A0D4CA3A4EAAQ28284976-4FA52E7C-9E5C-494C-97AC-F8DFB2BAD9D1Q28294134-D1FEB661-1FE5-4678-8D20-AD48520038B6Q28548580-72BA446F-AABF-41E2-A166-B9B7E07D2968Q30412650-47FAA650-AF4C-42D9-9759-92F85DF63D26Q30450875-9182A793-2E99-49B0-822B-846E56D0D5DFQ30480303-B5A39A41-B78F-4B53-827B-DF28FD05E3D9Q30675199-1BACF61C-7F3F-4CE7-82E1-388786AD4595Q30882939-0F2684A0-4777-4AC8-911E-462C8935D010Q33654733-4CE87383-A4FA-41AF-8731-66EC4758A569Q33695285-D8A8DB41-3D3C-4393-A14A-B8361AE634F5Q33759115-BC38CFBE-46D0-4715-A78C-1E864C042E0CQ33847243-2FAFD216-1600-4AA9-8145-C54C2C0D118FQ33865593-EA1BA819-F055-46D3-97D5-2BABB4C50D27Q34065405-EC9C601B-2210-4DEC-AB49-CE20718D74DBQ34098863-24503371-01D7-4B0E-9257-CA06DF682DA0Q34377621-79C73CBE-3E16-41BA-88B5-9B46E9C7BAECQ34449876-FA17FDE8-3748-4B94-9CDA-10F7EBED5D4EQ34605283-10433D6B-28EB-4B09-904B-FAD870FBCDF9Q34666072-50E5B926-7337-4281-84DD-B01B17D096EAQ35012024-63F4D41B-23AF-4AD0-90C1-9FC3EF7250B0Q35026264-11CCCC6A-F187-4E75-A6BF-C43A95525F9CQ35026302-31FFEF66-4386-44E2-B866-B771D62AB209Q35100867-816961A1-3A4B-4A05-B9BC-D06461723988Q35169275-3F799F5B-82B6-47EE-9872-DF5C99AF3A01Q35241502-467809EA-06AA-4DCF-93B8-D313F18D2451Q35537338-788D20FA-550A-477F-8AC3-91B53F8FC977
P2860
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Infliximab but not etanercept ...... patients with Crohn's disease.
@en
Infliximab but not etanercept ...... patients with Crohn's disease.
@nl
type
label
Infliximab but not etanercept ...... patients with Crohn's disease.
@en
Infliximab but not etanercept ...... patients with Crohn's disease.
@nl
prefLabel
Infliximab but not etanercept ...... patients with Crohn's disease.
@en
Infliximab but not etanercept ...... patients with Crohn's disease.
@nl
P2093
P50
P1433
P1476
Infliximab but not etanercept ...... patients with Crohn's disease.
@en
P2093
Catherine van Montfrans
Christiaan A Bauer
Daan W Hommes
Gijs R van den Brink
Inge Hoedemaeker
Jan M H Van den Brande
Sander J H van Deventer
P304
P356
10.1016/S0016-5085(03)00382-2
P407
P577
2003-06-01T00:00:00Z